GREEN PLANET MICROCAPS
ESG MICROCAP SPECIALISTS
Our treasure chest is filled with inspiring young companies that have innovative solutions to address a clean, low-carbon environment and to provide disruptive technologies to make life better
TOMORROW'S WINNERS TODAY
Why Investors are Buying BioLargo Shares
Before the News
Recently, the trading volume and price for BioLargo (BLGO: OTCQX) shares have been on the rise. The company has consistently provided progress reports as it developed and fleshed out its’ commercial technologies. Investors who take the time to understand the significance of what the company is doing are finding confidence in what they expect to happen in the near term. The heightened activity is fueled by expectations of major news on four fronts that could and should dramatically shift the trajectory of BioLargo’s stock. With each catalyst converging, the potential for rising share prices increases as the company advances.
Distribution Deal with a Global Medical Supplier
One of the most anticipated events is the nearing of the finalization of an agreement with a major player in the medical supply industry. BioLargo spent almost 4 years and $6 million gaining FDA clearance for BioClynse, a new gold standard in advanced wound care. More recently, the company has invested over $2,000,000 in the last year and their manufacturing partner, (Keystone Industries, as announced by the company) has invested over $5,000,000 in preparation for the launch of this product into a muti-billion-dollar industry. Dennis Calvert, BioLargo’s CEO has been on record with this deal as the company has been preparing to deliver large scale production to support the deal. Once manufacturing capacity is ready, then the relationship is expected to proceed. When finalized, everyone should be quite excited because this deal should bolster BioLargo’s valuation dramatically.
Cellinity Battery: A Game-Changing Innovation
Another catalyst fueling investor optimism is the continuing advancement of BioLargo’s Cellinity battery. This battery is rapidly gaining excitement because of its’ exceptional characteristics that stand out from current battery technology. Energy density is 2.9 times greater than lithium-ion batteries. Unlike, lithium-ion, Cellinity batteries are not capable of explosion and there is no risk of runaway fire, no self-discharging, 20-year life, no damage from excessive or rapid charging and there are no costly and geo-politically risky rare earths.
Crucially, it’s also just a good battery, meaning it’s efficient in how fast it can charge and discharge, and the fact that the battery can use all the energy stored in it (unlike Li-ion batteries which are often limited to around 75% efficiency).
The Cellinity battery is perfectly situated for Long Duration Energy Storage, the fastest growing segment in the energy storage sector. The Economist published “Clean Energy’s Next Trillion Dollar Business” predicting that Long Duration Energy Storage will be a trillion-dollar business.
The company has said that the battery is now ready for third party validation and management indicates it is in the works. Once that third party validation is available to the public, the news could have a memorable impact to BioLargos’ share valuation.
Record Sales of Pooph Products
BioLargo’s partnership with Pooph, Inc. is also a key driver of optimism among investors. The company’s products are already in over 40,000 stores, and that number is expected to grow to 80,000. Last year, Pooph sales broke all records sending the company into another record revenue year. We don’t have final year-end numbers yet, but we do know that Pooph numbers at the end of Q3 2024 already sent the year into record sales. Final year-end sales are expected soon.
Most analysts who have taken a deep dive into BioLargo believe that the Pooph sales all by themselves, without any other profit center, fully justifies the current valuation of the company.
PFAS Remediation: A Game-Changer for Removing Serious Health Hazards from Water
PFAS is a class of dangerous chemicals that have been found in water supplies across the U.S. and other countries. PFAS is a critical environmental challenge due to known health hazards and are linked to cancers, liver damage, hormonal disruption, immune system disruption, developmental issues, cholesterol levels, kidney disease, and more.
BioLargo is a recognized leader in PFAS removal and destruction and is advancing a leading solution to this global problem. In recent interviews, Dennis Calvert has indicated that new relationships of collaboration and validation are starting with the EPA and are in the works. Early indications suggest a robust interest in BioLargo’s PFAS solutions with projects already amounting to over $100 million in the pipeline and growing. The company is ready to install its first PFAS Aqueous Electrostatic Collector at a water treatment facility in New Jersey and should be ready to go live as soon the ground thaws and construction is ready for the installation. BioLargo has the system all crated and ready for shipment.
PFAS has been called a $17 trillion per year global problem. As the company finds increased adoption, this has the potential to be a significant value driver.
Break-Even Cash Flow and Minimal Supply of Shares
As the company continues to improve financial performance, they can use available cash flow to expand and advance their portfolio of commercial opportunities. This also creates less pressure to issue new shares that could weigh on share price performance.
Almost No Debt
The most recent financial statements indicate no significant debt.
Conclusion: Why Investors Are Bullish on BioLargo
In conclusion, there are several key factors that are converging that make now an opportune time for investors to buy and hold BioLargo shares. From a major distribution deal with a global medical supplier to the advancement of game-changing products like the Cellinity battery and Pooph, to BioLargo’s unrivaled technology for PFAS remediation, the company is positioned for extraordinary growth. Savvy investors are loading up now, anticipating substantial returns as these developments unfold.
The old adage, “slow and steady wins the race” seems applicable. This company has been at it for a long time and it has taken years to get to this point.
Are we sure that we are finally at an inflection point?
As always, do your own due diligence and make your own determination. Refer to BioLargo, Inc. public filings on SEC.GOV.
Legal Disclosures and Disclaimers
Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.
Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.
Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.
Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.
Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from. Green Planet Microcaps was compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.
Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.